Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA4 | P22748 | 4/20 | 0.40 |
| ▸ | CA7 | P43166 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29681708 | 1.00 | KEAP1 (0.44) | KEAP1BRD4GRIA2CA12CA9 | |
| Hydrochloric Acid SCHEMBL7399331 | 0.98 | KEAP1 (0.43) | KEAP1BRD4GRIA2CA12CA9 | |
| SCHEMBL18638475 | 0.84 | KDM4E (0.46) | KEAP1BRD4GRIA2CA12CA9 | |
| SCHEMBL29412491 | 0.84 | KEAP1 (0.40) | KEAP1BRD4GRIA2CA12CA9 | |
| SCHEMBL18065115 | 0.83 | CYP2A6 (0.47) | KEAP1BRD4GRIA2CA12CA9 | |
| SCHEMBL22695019 | 0.80 | OPRL1 (0.36) | KEAP1BRD4GRIA2CA12CA9 | |
| SCHEMBL7524437 | 0.79 | PARP1 (0.44) | KEAP1BRD4GRIA2CA12CA9 | |
| SCHEMBL2087337 | 0.78 | CA12 (0.35) | KEAP1BRD4GRIA2CA12CA9 | |
| SCHEMBL710185 | 0.78 | KEAP1 (0.50) | KEAP1GRIA2CA12CA9CA1 | |
| SCHEMBL16852846 | 0.75 | KEAP1 (0.47) | KEAP1GRIA2CA12CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 460 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3286166-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2020-05-13 | — | — | EP | claimed |
| US-10221129-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2019-03-05 | — | — | US | claimed |
| US-20180086697-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-29 | — | — | US | claimed |
| EP-3286166-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-02-28 | — | — | EP | claimed |
| CN-105189498-B | Geminally substituted cyanoethylpyrazolopyridinones as JANUS kinase inhibitors | 默沙东公司 | 2017-06-27 | — | — | CN | claimed |
| WO-2016172424-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-27 | — | — | WO | claimed |
| EP-1664027-B1 | SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2009-12-30 | — | — | EP | claimed |
| EP-1664023-B1 | SUSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2008-08-13 | — | — | EP | claimed |
| US-7390820-B2 | Substituted quinolinone derivatives and methods of use | AMGEN INC. (US) | 2008-06-24 | — | — | US | claimed |
| US-7320992-B2 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | AMGEN INC. (US) | 2008-01-22 | — | — | US | claimed |
| US-4228075-A | Novel sulfam(na)phthaleins | POLAROID CORPORATION (US) | 1980-10-14 | — | — | US | claimed |
| US-4210752-A | Synthesis of substituted sulfam(na)phthaleins | POLAROID CORPORATION (US) | 1980-07-01 | — | — | US | claimed |
| US-4204061-A | Sulfam(na)phthaleins | POLAROID CORPORATION (US) | 1980-05-20 | — | — | US | claimed |
| US-4195180-A | Sulfam (na) phthaleins | POLAROID CORPORATION (US) | 1980-03-25 | — | — | US | claimed |
| US-4191689-A | Benzisothiazole-1,1-dioxide and naphtho-1,2-thiazine-1,1-dioxide compounds | POLAROID CORPORATION (US) | 1980-03-04 | — | — | US | claimed |
| US-4186001-A | IRREVERSIBLE CLEAVAGE IN ALKALINE SOLUTION TO FORM COLORLESS COMPOUND | POLAROID CORPORATION (US) | 1980-01-29 | — | — | US | claimed |
| US-4178446-A | Sulfam(na)phthaleins | POLAROID CORPORATION (US) | 1979-12-11 | — | — | US | claimed |
| US-4178447-A | Novel synthesis of 3,3-substituted dihydrobenzisothiazole-1,1-dioxides and -2,3-dihydronaphtho-1,2-thiazine-1,1-dioxides | POLAROID CORPORATION (US) | 1979-12-11 | — | — | US | claimed |
| EP-0001290-A1 | Substituted 2,3-dihydrobenz-(d)-isothiazole-1,1-dioxides and 2,3-dihydronaphtho-(1,8-de)-1,2-thiazine-1,1-dioxides | POLAROID CORPORATION (US) | 1979-04-04 | — | — | EP | claimed |
| US-4139381-A | DIFFUSION TRANSFER, ANTIFOGGING AGENTS | POLAROID CORPORATION (US) | 1979-02-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221129-B2 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, POLR2E, POLR2H | KEAP1 2636/4885BRD4 1829/4885GRIA2 4494/4885 |
| US-20180086697-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | KEAP1 2636/4885BRD4 1829/4885GRIA2 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.